Alexandra Quarti
About Alexandra Quarti
Dr. Alexandra Quarti, DVM, is Vice President of Medical Operations at Inspire Veterinary Partners (IVP) and has served in this role since June 2022. She is 51 years old and holds a Doctor of Veterinary Medicine from Ross University School of Veterinary Medicine (2007), with her clinical year at Cornell University; she maintains active veterinary licenses in nine states . In 2025, IVP’s operations continued to scale, with quarterly revenues rising from ~$3.3M in Q4 2024 to ~$4.3M in Q3 2025, while EBITDA losses narrowed versus Q4 2024, framing the operating backdrop for her tenure overseeing medical operations .
Company operating performance context (quarterly):
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 |
|---|---|---|---|---|
| Revenue ($) | 3,321,136* | 3,639,209 | 4,283,534 | 4,316,132 |
| EBITDA ($) | (2,757,662)* | (1,731,916)* | (1,597,677)* | (1,636,668)* |
| Net Income ($) | (3,966,722)* | (2,415,036)* | (3,034,568)* | (2,526,273)* |
| EBITDA Margin (%) | (83.0%)* | (47.6%)* | (37.3%)* | (37.9%)* |
| Values retrieved from S&P Global. An asterisk indicates values without document citations. |
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Community Veterinary Partners (CVP) | Northeast Region Director of Operations (led medical and business ops for 24 hospitals) | 2019–2022 | Led regional medical quality and business outcomes, financial management, and talent development across multi-site portfolio . |
| Banfield Pet Hospitals | Associate Doctor → Director of Veterinary Quality (promoted 2009) | 2008–2019 | Oversaw medical quality, compliance, and operational performance for 20+ hospitals in New England; implemented systems to elevate care standards and growth . |
| Private Practice (Old Lyme, CT) | Veterinarian | 2007–2008 | Early clinical practice experience . |
External Roles
No public company board or external directorships are disclosed for Dr. Quarti in IVP’s 2024–2025 SEC filings referencing executive officer bios .
Fixed Compensation
Named Executive Officer (NEO) compensation (salary and benefits):
| Year | Base Salary ($) | All Other Compensation ($) | Total ($) |
|---|---|---|---|
| 2024 | 198,240 | 11,766 | 210,006 |
| 2023 | 194,272 | 10,078 | 204,350 |
All Other Compensation (2024 breakdown):
| 401(k) Matching ($) | Health Benefit Premiums ($) |
|---|---|
| 2,047 | 9,718 |
Notes:
- The 2025 10-K presents substantially the same 2024/2023 totals for Dr. Quarti (minor formatting differences vs. the proxy) .
Performance Compensation
Summary of incentive and equity outcomes for Dr. Quarti:
| Incentive Type | 2023 | 2024 | Vesting / Terms |
|---|---|---|---|
| Annual Cash Bonus | — | — | No bonuses paid; no plan metrics disclosed for Dr. Quarti . |
| Non-Equity Incentive Plan Comp | — | — | None paid . |
| Stock Options/RSUs/PSUs (grants) | — | — | No equity grants shown in NEO table . |
| Outstanding Equity Awards (year-end) | None at 12/31/2023 | None at 12/31/2024 | Company discloses no outstanding awards for NEOs at 12/31/2024 . |
Performance metric design and payout detail: Not disclosed for Dr. Quarti. CEO/CFO metric grids are provided, but no plan metrics are specified for Dr. Quarti in the filings reviewed .
Equity Ownership & Alignment
| Date (As of) | Class A Shares | Class B Shares | Notes |
|---|---|---|---|
| Oct 14, 2025 (DEF 14A) | — | — | Listed in beneficial ownership table with no shares; “—” shown for both classes . |
| Jan 29, 2025 (10-K) | — | — | No shares reported in ownership table . |
| Form 3 filed Aug 25, 2025 | — | — | Initial Statement of Beneficial Ownership: “No securities are beneficially owned” . |
Additional alignment observations:
- No options/RSUs/PSUs outstanding as of 12/31/2024; thus no vesting overhang or scheduled selling pressure from expiring awards .
- No pledging or hedging arrangements are disclosed for Dr. Quarti in the beneficial ownership sections reviewed .
Employment Terms
- Employment agreement and CoC/severance: Filings disclose change-in-control/severance terms only for the CEO and CFO; the company states it has no change-in-control agreements with any executive officers other than the CEO, implying none disclosed for Dr. Quarti .
- Executive officer status: Listed as an executive officer (Vice President of Medical Operations) with age and biography included in the executive officer roster .
- Compensation governance: The Compensation Committee (independent directors Anne Murphy, Chair, and Erinn Thomas‑Mackey) oversees executive pay and equity plans; the committee met four times in 2024 .
Performance & Track Record
- Operating leadership: Oversees medical operations, quality, and clinician support. IVP highlighted 2025 YTD veterinary doctor hiring surpassing 2024 by 500% and referenced plans to leverage new medical leaders under Dr. Quarti’s leadership; she emphasized flexible schedules and support structures for doctors to deliver world-class care .
- Background and credentials: 15+ years in veterinary leadership across CVP and Banfield; DVM from Ross University, clinical year at Cornell; multi-state licensure .
Investment Implications
- Pay-for-performance alignment: For 2023–2024, compensation for Dr. Quarti was almost entirely fixed (salary and benefits) with no cash bonus, no non-equity incentive pay, and no equity grants disclosed—limited measurable linkage to performance KPIs and no multi-year vesting alignment .
- Insider selling pressure: Nil. Beneficial ownership tables and Form 3 indicate no holdings and no outstanding awards—minimal risk of event-driven selling tied to vesting or option expirations .
- Retention risk: Absence of disclosed change-in-control protection for executives other than the CEO and no outstanding equity reduce retention “hooks” for a key operator in a consolidating industry where competitors often use equity-heavy packages .
- Execution dependence: Medical operations leadership is central to IVP’s growth and clinician retention narrative. While revenue trended higher through 2025, profitability remains negative, underscoring ongoing execution needs in clinic productivity and cost leverage that intersect with Dr. Quarti’s remit .